Virtual Library
Start Your Search
J. Nie
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-053 - Efficacy and Safety of Extended Therapy with Endostar Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Study (ID 1393)
09:30 - 09:30 | Author(s): J. Nie
- Abstract
Background:
It is known that the addition of endostar (recombinant human endostatin, a novel broad-spectrum inhibitor of tumor angiogenesis) to chemotherapy resulted in a significant effective benefit in the treatment of patients with advanced non–small cell lung cancer (NSCLC). Previous research showed that multicycle application of angiogenetic drug combined with chemotherapy might prolong overall survival of NSCLC. However, the optimal treatment duration of endostar and chemotherapy remains uncertain.
Methods:
A retrospective analysis of ≥ 4 cycles versus < 4 cycles of endostar combined with platinum-based doublet chemotherapy(PBDC) was performed in patients with advanced NSCLC. For efficacy assessments, patients received ≥ 4 cycles of therapy (extended group) were compared with those who received less than 4 cycles but not because of tumor progression (control group). Toxicity analyses were performed for all patients.
Results:
A total of 232 patients were enrolled, of whom 128 patients completed at least four cycles of the therapy (extended group), 64 patients ceased their therapy before 4 cycles not because of progression(control group). The median progress free survival(PFS) was 8.2 months versus 5.4 months in extended group and control group (p=0.027), and the median overall survival(OS) was 22.5 months versus 13.6 months (p=0.000), respectively. Subgroup analysis showed that, among the EGFR mutation-positive patients, the control group seemed to result in a trend toward survival benefit according to the Kaplan-Meier curves, although the differences are not statistically significant. Hematological toxicity and fatigue occurred more frequently in patients received 4 or more cycles (p﹤0.05), but no statistically significant difference was detected in all grade ≥3 adverse events. Figure 1Figure 2
Conclusion:
Extended treatment of endostar combined with chemotherapy exhibited increased survival and acceptable toxicity in previously untreated patients with NSCLC, supporting further evaluation in larger prospective studies.
